AFX 2421
Alternative Names: AFX-2421Latest Information Update: 28 Apr 2025
At a glance
- Originator Afecta Pharmaceuticals
- Class Antiparkinsonians; Small molecules; Urologics
- Mechanism of Action Neurotransmitter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Interstitial cystitis
- Discontinued Parkinson's disease
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Interstitial-cystitis in USA
- 26 Mar 2021 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route) before March 2021 (Afecta Pharmaceuticals' pipeline, March 2021)
- 26 Mar 2021 Preclinical trials in Interstitial cystitis in USA (unspecified route) before March 2021 (Afecta Pharmaceuticals' pipeline, March 2021)